Spiral Therapeutics to Attend 2024 Wedbush PacGrow Healthcare Conference

Spiral Therapeutics, Inc., located in South San Francisco, announced its participation in the 2024 Wedbush PacGrow Healthcare Conference, set for August 13-14 in New York. Spiral's CEO and founder, Hugo Peris, will join a panel discussion on otology on August 14 at 1:45 PM ET. Additionally, Spiral's management team will conduct one-on-one meetings with investors throughout the event.

Spiral Therapeutics is at the forefront of creating innovative treatments for inner ear disorders, including hearing loss and balance issues. The company utilizes its unique Minimally Invasive Cochlear System (MICS™), which allows for targeted, long-lasting, and minimally invasive drug delivery directly to the cochlea. This technology aims to meet the critical medical needs of patients with inner ear conditions.

Among Spiral's key developmental projects is SPT-2101, a dexamethasone formulation designed for precise intratympanic delivery. SPT-2101 has delivered encouraging outcomes in clinical trials, particularly for patients with Meniere's disease, by significantly reducing the number of definitive vertigo days (DVDs) and enhancing their overall quality of life.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!